322P - Rapid genetic screening experience among endometrial cancer about Lynch syndrome by surgeon

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Endometrial Cancer
Pathology/Molecular Biology
Presenter Min Kyu Kim
Citation Annals of Oncology (2016) 27 (suppl_9): ix94-ix103. 10.1093/annonc/mdw585
Authors M.K. Kim
  • Obstetrics And Gynecology, Samsung Changwon Hospital Sung Kyun Kwan University, 630-723 - Changwon/KR

Abstract

Background

Lynch syndrome increase risk of mostly endometrial cancer and colorectal cancer. There is not much study about detecting algorithm among Korean population by gynecologic oncology surgeon. We undertook this study to investigate this.

Methods

A retrospective review of endometrial cancer patients who was counseled about Lynch syndrome in Department of Obstetrics and gynecology, Samsung Changwon Hospital by single surgeon was done. Clinical information was extracted from the medical record including age, family and personal history of cancer, immunohistochemistry(IHC), microsatellite instability test(MSI), and gene sequencing results. Risk management and posttest education after result were offered about risk reducing options and cascade testing for affected individual

Results

Total test was 16.There were two germline mutations (both MSH2) (c.23C>T (p.Thr8Met), c.187delG (p.Val63*).Both were negative for MSH2 IHC, But no patient matched criteria of Amsterdam. Four variation of unknown significance (VUS) was found (Three MSH2 and One MLH1).Among those all were abnormal in IHC and there was only one Amsterdam criteria matched patient. There were two unstable MSI patients, one was MSH2 germline mutation and the other was MSH2 VUS. Median age was 57(41∼76).Most cases were endometrioid type (11/16, 69%).Seventy five percent were stage I(12/16).

Conclusions

We found two MSH2 germline mutation patients among this population. Gynecologic oncology surgeon can be adapted to develop the ability to assess and evaluate genetic risk among endometrial cancer.

Clinical trial indentification

Legal entity responsible for the study

N/A

Funding

N/A

Disclosure

All authors have declared no conflicts of interest.